ATXS — Astria Therapeutics Share News
0.000.00%
Last trade - 00:00- $718.13m
- $585.73m
Brief: Astria Therapeutics Receives Fast Track Designation For STAR-0215
Astria Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Astria Therapeutics Reports First Quarter Financial Results
Astria Therapeutics Inc expected to post a loss of 55 cents a share - Earnings Preview
Brief: Astria Therapeutics Names Andrea Matthews Chief Business Officer
Astria Therapeutics gains as quarterly loss narrows
Astria Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Astria Therapeutics Reports Fourth Quarter And Full Year 2022 Financial Results And Provides A Corporate Update
Astria Therapeutics Inc expected to post a loss of 71 cents a share - Earnings Preview
Astria Therapeutics Inc expected to post a loss of 71 cents a share - Earnings Preview
Brief: Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Astria Therapeutics Presents Data Supporting STAR-0215 Profile For Hereditary Angioedema
Brief: Astria Therapeutics Initiates ALPHA-STAR Phase 1B/2 Clinical Trial Of STAR-0215 In People With HAE
Brief: Deep Track Capital Reports 7.32% Passive Stake In Astria Therapeutics As Of December 15, 2022 - SEC Filing
U.S. STOCKS ON THE MOVE-Trip.com, Verizon Communications, Netflix
U.S. STOCKS ON THE MOVE-Reviva, AbCellera, Verizon
Brief: Catabasis Pharmaceuticals Renames To Astria Therapeutics
Catabasis Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Catabasis Pharmaceuticals Reports Second Quarter 2021 Financial Results And Provides A Corporate Update